Aisling Capital Management as of Sept. 30, 2020
Portfolio Holdings for Aisling Capital Management
Aisling Capital Management holds 15 positions in its portfolio as reported in the September 2020 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Bridgebio Pharma (BBIO) | 47.8 | $150M | 4.0M | 37.52 | |
| Eidos Therapeutics | 18.1 | $57M | 1.1M | 50.53 | |
| Harmony Biosciences Hldgs In (HRMY) | 9.1 | $29M | 843k | 33.90 | |
| Syndax Pharmaceuticals (SNDX) | 4.8 | $15M | 1.0M | 14.76 | |
| Avrobio Ord (AVRO) | 4.2 | $13M | 1.0M | 13.02 | |
| Aeglea Biotherapeutics | 3.8 | $12M | 1.7M | 7.09 | |
| Poseida Therapeutics I (PSTX) | 3.0 | $9.3M | 1.0M | 8.87 | |
| Verona Pharma Plc ads (VRNA) | 2.7 | $8.3M | 1.3M | 6.24 | |
| Atreca Cl A Com (BCEL) | 1.7 | $5.4M | 388k | 13.97 | |
| Zosano Pharma Corp | 1.4 | $4.4M | 2.7M | 1.62 | |
| Obseva Sa | 1.1 | $3.4M | 1.4M | 2.48 | |
| Marker Therapeutics Ord | 1.0 | $3.0M | 2.0M | 1.50 | |
| Aclaris Therapeutics (ACRS) | 0.5 | $1.6M | 635k | 2.57 | |
| Sunesis Pharmaceuticals Inc Ne | 0.4 | $1.3M | 1.0M | 1.25 | |
| Nabriva Therapeutics SHS | 0.3 | $1.0M | 1.9M | 0.53 |
